Assessment of Volume-targeted Ventilation in Patients With Neuromuscular

Status Recruiting

Clinical Trial Summary

Assessment of safety and efficacy of volume-targeted ventilation in patients with neuromuscular disease.

Clinical Trial Description

Patients with neuromuscular diseases (NMD) can suffer from breathing difficulties requiring treatment with a breathing device known as non-invasive ventilation (NIV). NIV aims to support the lungs in removing the waste gas, carbon dioxide (CO2). This is important because patients with high CO2 levels tend to have worse clinical outcomes. NIV delivers different pressures to the airway when the patient breathes in and when they breathe out. Usually, the pressures it delivers are fixed; i.e. they do not change breath-to-breath. Newer technology allows the machine to independently change the pressures, depending on various patient factors it can measure. There are a small number of studies that suggested that these 'auto-titrating' machines may improve control of carbon dioxide but further work is needed. One of these modes allows us to set a target volume that should be delivered to the patient each breath, and the machine changes settings to deliver this target volume, in response to changing patient parameters. We aim to investigate the safety and efficacy of this volume-targeted NIV (VT-NIV), in order to generate data to design a randomised controlled trial to compare VT-NIV with fixed-NIV. Patients with NMD who use fixed-NIV will be admitted for a two-night stay to our centre. On the first night, their CO2 control will be assessed on their current ventilator. On the second night, they will be switched to the VT-NIV mode. They will be discharged and asked to use the new mode for three months. Individuals with well-controlled CO2 with their usual mode will allow us to assess the safety of VT-NIV, and individuals with poorly-controlled CO2 will allow us to assess its efficacy. At three months, they will attend an outpatient visit, where use of the new mode will be assessed through data download from the machine and completion of questionnaires. ;

Study Design

Related Conditions & MeSH terms

Neuromuscular Diseases

Clinical Trial Details

NCT number	NCT06339580
Study type	Interventional
Source	Guy's and St Thomas' NHS Foundation Trust
Contact	Patrick Murphy
Phone	02071888070
Email	Patrick.murphy@gstt.nhs.uk
Status	Recruiting
Phase	Phase 2
Start date	April 9, 2024
Completion date	April 2026

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03548779` - North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2	N/A
Completed	`NCT04435093` - Digitalization Playful Module of Motor Function Measure Assessment for Children With Neuromuscular Disorders, MFM-Play Pilot Study.
Not yet recruiting	`NCT04089696` - Validation of the "ExSpiron©" in Patients With ALS	N/A
Not yet recruiting	`NCT05785546` - Elaboration of a Pronostic Score of Changes on Wheelchair's Seating System
Completed	`NCT01313325` - Hippotherapy to Improve the Balance of Children With Movement Disorders	N/A
Recruiting	`NCT04098094` - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Active, not recruiting	`NCT05070624` - The Peer Support Study	N/A
Completed	`NCT04729920` - Home Use of Mechanical Insufflation/Exsufflation Devices in Neuromuscular Diseases
Recruiting	`NCT04581577` - Perceptions of the Clinical and Psychosocial Impact of Covid-19 in Patients With Neuromuscular and Neurological Disorders
Completed	`NCT06428864` - Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
Enrolling by invitation	`NCT05539456` - Reliability and Validity of the Turkish Version of the PedsQL 3.0 Neuromuscular Module for 2-to 4- Year-old
Completed	`NCT05353738` - Efficacy of Vaccination Against COVID-19 in Patients Presenting a Neuromuscular Disease With Severe Amyotrophy
Recruiting	`NCT04541602` - Detection of Neuromuscular Complications in Critically Ill Patients
Completed	`NCT03394859` - Electronic Medical Records and Genomics (eMERGE) Phase III
Enrolling by invitation	`NCT05099107` - Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment	N/A
Completed	`NCT05070910` - NDT Effectiveness Study	N/A
Recruiting	`NCT04100993` - Multisystem and Autonomic Complications of NMD on Long-term NIV
Recruiting	`NCT04986059` - Effects of Pre-event Massage on Muscle Activity	N/A
Completed	`NCT01022931` - Epidemiology and Clinical Presentation of H1N1 Infection in Children in Geneva	N/A
Terminated	`NCT03353064` - Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of Volume-targeted Ventilation in Patients With Neuromuscular Disease — VT-NMD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms